In the BioHarmony Drug Report Database

"Preview" Icon

Denosumab

Prolia, Xgeva (denosumab) is an antibody pharmaceutical. Denosumab was first approved as Prolia on 2010-05-26. It is used to treat osteoporotic fractures and postmenopausal osteoporosis in the USA. It has been approved in Europe to treat bone fractures, bone resorption, neoplasm metastasis, and postmenopausal osteoporosis. The pharmaceutical is active against tumor necrosis factor ligand superfamily member 11.

 

Trade Name

 

Prolia, Xgeva
 

Common Name

 

denosumab
 

ChEMBL ID

 

CHEMBL1237023
 

Indication

 

bone fractures, bone resorption, neoplasm metastasis, osteoporotic fractures, postmenopausal osteoporosis
 

Drug Class

 

Monoclonal antibodies: fully human, bone target

Image (chem structure or protein)

Denosumab structure rendering